{
  "docId": "019de075-8a55-750a-8008-603750933d71",
  "docSlug": "da8608bdf4ad385699d1340db7dce185",
  "documentTitle": "Erasca | Investor Presentation Deck | 56 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 31,
  "pageCount": 56,
  "prevPage": 30,
  "nextPage": 32,
  "slideType": "traction",
  "function": "show_traction",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a process-oriented flow to demonstrate clinical validation milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-8a55-750a-8008-603750933d71/31",
  "deckHref": "/decks/019de075-8a55-750a-8008-603750933d71",
  "deckJsonHref": "/decks/019de075-8a55-750a-8008-603750933d71.json",
  "deckAnchorHref": "/decks/019de075-8a55-750a-8008-603750933d71#slide-31",
  "components": [
    {
      "bbox": {
        "h": 0.55,
        "w": 0.9,
        "x": 0.05,
        "y": 0.18
      },
      "kind": "diagram",
      "text": "Five-stage process flow showing clinical milestones: Target PK, No DDI, Safely combined, Monotherapy efficacy, Combination efficacy.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3d9ae647-9843-473b-93b6-a9cec36eb341",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.2,
        "y": 0.78
      },
      "kind": "paragraph",
      "text": "Further evaluation of ERAS-007 + encorafenib and cetuximab (EC) in patients with EC-naïve BRAFm CRC is ongoing in HERKULES-3",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e67dc04f-18b4-4312-9157-c2376c1bac3e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.6,
        "x": 0.03,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Note: PK = pharmacokinetics; DDI = drug-drug interaction; Approved agents evaluated in clinic are osimertinib, encorafenib, cetuximab, and palbociclib",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5a25c1ca-72ed-44d9-83d2-491bf4740bc0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.12,
        "w": 0.94,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Early clinical data reinforce potential combinability of ERAS-007 as a backbone to treat patients with GI cancers including BRAFm CRC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5fb3c012-105c-4c21-8b83-ef3c2683ad92",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}